ArticleThe Journal of infection2022
Antibody titers and breakthrough infections with Omicron SARS-CoV-2.
Article in The Journal of infection, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Trial
- SARS-CoV-2 breakthrough infection incidence, risk factors, and antibody correlates in Belgian nursing homes residents and staff (2021-2022).Archives of public health = Archives belges de sante publique · 2026Article
- SARS CoV-2 seroprevalence and rising antibody titres across successive pandemic waves in accra, Ghana: August 2020 to January 2022.Scientific reports · 2026Article
- Impact of First SARS-CoV-2 Infection Variant on Serological Responses Against Omicron: Findings From the SIREN Study.Influenza and other respiratory viruses · 2026Article
- Comparison of long-term anti-RBD SARS-CoV-2 antibody response following different vaccination schemes in Tunisia.La Tunisie medicale · 2024Article
- Evaluating the risk of SARS-CoV-2 reinfection with the Omicron or Delta variant in Wales, UK.PloS one · 2024Article
- Unveiling a New Perspective on Distinguishing Omicron Breakthrough Cases and Postimmune COVID-19-Naive Individuals: Insights from Antibody Profiles.Microbiology spectrum · 2023Article
- Protection against Severe Illness versus Immunity-Redefining Vaccine Effectiveness in the Aftermath of COVID-19.Microorganisms · 2023Review
- Prevalence and Clinical Outcome of Omicron Breakthrough Infection in Patients With Hematologic Disease: A Prospective Observational Cohort Study.HemaSphere · 2023Article
- Durability of Immune Response after Application of a Third Dose of SARS-CoV-2 Vaccination in Liver Transplant Recipients.Vaccines · 2023Article
- Article
- Review
- Broadly Reactive SARS-CoV-2-Specific T-Cell Response and Participation of Memory B and T Cells in Patients with Omicron COVID-19 Infection.Journal of immunology research · 2023Article
- A 12-month follow-up of the immune response to SARS-CoV-2 primary vaccination: evidence from a real-world study.Frontiers in immunology · 2023Article
- Article
- Glucocorticoid use as a cause of non-cellular immune response to SARS-Cov2 Spike in patients with immune system diseases.Journal of autoimmunity · 2022Article
- Article
- Article
- SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.Journal of medical virology · 2022Observational
- Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?Viruses · 2022Review
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.